Cargando…
Metabolic signatures differentiate ovarian from colon cancer cell lines
BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499939/ https://www.ncbi.nlm.nih.gov/pubmed/26169745 http://dx.doi.org/10.1186/s12967-015-0576-z |
_version_ | 1782380860793683968 |
---|---|
author | Halama, Anna Guerrouahen, Bella S Pasquier, Jennifer Diboun, Ilhem Karoly, Edward D Suhre, Karsten Rafii, Arash |
author_facet | Halama, Anna Guerrouahen, Bella S Pasquier, Jennifer Diboun, Ilhem Karoly, Edward D Suhre, Karsten Rafii, Arash |
author_sort | Halama, Anna |
collection | PubMed |
description | BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such approaches have been extensively implemented in order to provide biomarkers for monitoring of the disease as well as to improve readouts of therapeutic impact. The application of metabolomics to the study of cancer is especially beneficial, since it reflects the biochemical consequences of many cancer type-specific pathophysiological processes. Here, we characterize metabolic profiles of colon and ovarian cancer cell lines to provide broader insight into differentiating metabolic processes for prospective drug development and clinical screening. METHODS: We applied non-targeted metabolomics-based mass spectroscopy combined with ultrahigh-performance liquid chromatography and gas chromatography for the metabolic phenotyping of four cancer cell lines: two from colon cancer (HCT15, HCT116) and two from ovarian cancer (OVCAR3, SKOV3). We used the MetaP server for statistical data analysis. RESULTS: A total of 225 metabolites were detected in all four cell lines; 67 of these molecules significantly discriminated colon cancer from ovarian cancer cells. Metabolic signatures revealed in our study suggest elevated tricarboxylic acid cycle and lipid metabolism in ovarian cancer cell lines, as well as increased β-oxidation and urea cycle metabolism in colon cancer cell lines. CONCLUSIONS: Our study provides a panel of distinct metabolic fingerprints between colon and ovarian cancer cell lines. These may serve as potential drug targets, and now can be evaluated further in primary cells, biofluids, and tissue samples for biomarker purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0576-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4499939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44999392015-07-14 Metabolic signatures differentiate ovarian from colon cancer cell lines Halama, Anna Guerrouahen, Bella S Pasquier, Jennifer Diboun, Ilhem Karoly, Edward D Suhre, Karsten Rafii, Arash J Transl Med Research BACKGROUND: In this era of precision medicine, the deep and comprehensive characterization of tumor phenotypes will lead to therapeutic strategies beyond classical factors such as primary sites or anatomical staging. Recently, “-omics” approached have enlightened our knowledge of tumor biology. Such approaches have been extensively implemented in order to provide biomarkers for monitoring of the disease as well as to improve readouts of therapeutic impact. The application of metabolomics to the study of cancer is especially beneficial, since it reflects the biochemical consequences of many cancer type-specific pathophysiological processes. Here, we characterize metabolic profiles of colon and ovarian cancer cell lines to provide broader insight into differentiating metabolic processes for prospective drug development and clinical screening. METHODS: We applied non-targeted metabolomics-based mass spectroscopy combined with ultrahigh-performance liquid chromatography and gas chromatography for the metabolic phenotyping of four cancer cell lines: two from colon cancer (HCT15, HCT116) and two from ovarian cancer (OVCAR3, SKOV3). We used the MetaP server for statistical data analysis. RESULTS: A total of 225 metabolites were detected in all four cell lines; 67 of these molecules significantly discriminated colon cancer from ovarian cancer cells. Metabolic signatures revealed in our study suggest elevated tricarboxylic acid cycle and lipid metabolism in ovarian cancer cell lines, as well as increased β-oxidation and urea cycle metabolism in colon cancer cell lines. CONCLUSIONS: Our study provides a panel of distinct metabolic fingerprints between colon and ovarian cancer cell lines. These may serve as potential drug targets, and now can be evaluated further in primary cells, biofluids, and tissue samples for biomarker purposes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-015-0576-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-14 /pmc/articles/PMC4499939/ /pubmed/26169745 http://dx.doi.org/10.1186/s12967-015-0576-z Text en © Halama et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Halama, Anna Guerrouahen, Bella S Pasquier, Jennifer Diboun, Ilhem Karoly, Edward D Suhre, Karsten Rafii, Arash Metabolic signatures differentiate ovarian from colon cancer cell lines |
title | Metabolic signatures differentiate ovarian from colon cancer cell lines |
title_full | Metabolic signatures differentiate ovarian from colon cancer cell lines |
title_fullStr | Metabolic signatures differentiate ovarian from colon cancer cell lines |
title_full_unstemmed | Metabolic signatures differentiate ovarian from colon cancer cell lines |
title_short | Metabolic signatures differentiate ovarian from colon cancer cell lines |
title_sort | metabolic signatures differentiate ovarian from colon cancer cell lines |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499939/ https://www.ncbi.nlm.nih.gov/pubmed/26169745 http://dx.doi.org/10.1186/s12967-015-0576-z |
work_keys_str_mv | AT halamaanna metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT guerrouahenbellas metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT pasquierjennifer metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT dibounilhem metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT karolyedwardd metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT suhrekarsten metabolicsignaturesdifferentiateovarianfromcoloncancercelllines AT rafiiarash metabolicsignaturesdifferentiateovarianfromcoloncancercelllines |